冯思齐, 周欣, 张元钟, 杨宁, 周思齐, 熊彩建, 金青子, 陶康, 徐新荣. 驻景丸加减方治疗肝肾不足型干性年龄相关性黄斑变性的临床研究[J]. 南京中医药大学学报, 2024, 40(5): 521-526. DOI: 10.14148/j.issn.1672-0482.2024.0521
引用本文: 冯思齐, 周欣, 张元钟, 杨宁, 周思齐, 熊彩建, 金青子, 陶康, 徐新荣. 驻景丸加减方治疗肝肾不足型干性年龄相关性黄斑变性的临床研究[J]. 南京中医药大学学报, 2024, 40(5): 521-526. DOI: 10.14148/j.issn.1672-0482.2024.0521
FENG Siqi, ZHOU Xin, ZHANG Yuanzhong, YANG Ning, ZHOU Siqi, XIONG Caijian, JIN Qingzi, TAO Kang, XU Xinrong. Clinical Study on the Treatment of Dry Age-Related Macular Degeneration of Liver and Kidney Insufficiency Type with Modified Zhujing Pills[J]. Journal of Nanjing University of traditional Chinese Medicine, 2024, 40(5): 521-526. DOI: 10.14148/j.issn.1672-0482.2024.0521
Citation: FENG Siqi, ZHOU Xin, ZHANG Yuanzhong, YANG Ning, ZHOU Siqi, XIONG Caijian, JIN Qingzi, TAO Kang, XU Xinrong. Clinical Study on the Treatment of Dry Age-Related Macular Degeneration of Liver and Kidney Insufficiency Type with Modified Zhujing Pills[J]. Journal of Nanjing University of traditional Chinese Medicine, 2024, 40(5): 521-526. DOI: 10.14148/j.issn.1672-0482.2024.0521

驻景丸加减方治疗肝肾不足型干性年龄相关性黄斑变性的临床研究

Clinical Study on the Treatment of Dry Age-Related Macular Degeneration of Liver and Kidney Insufficiency Type with Modified Zhujing Pills

  • 摘要:
      目的  评价驻景丸加减方治疗肝肾不足型干性年龄相关性黄斑变性(AMD)的临床疗效。
      方法  64例肝肾不足型干性AMD患者随机分为试验组和对照组各32例。对照组予莱视盯胶囊口服治疗,试验组予驻景丸加减方颗粒剂口服治疗,2组疗程均为3个月。治疗前后观察2组患者中医证候积分、视力、眼底自发荧光(AF)、黄斑中心凹5 mm内玻璃疣面积变化情况,检测血浆超氧化物歧化酶(SOD)、谷胱甘肽过氧化物酶(GSH-Px)活性和丙二醛(MDA)水平变化情况。
      结果  治疗后,试验组中医证候积分均明显减少(P < 0.05,P < 0.01),中医证候疗效优于对照组(P < 0.01);试验组患者视力明显提高、AF显著减弱、玻璃疣的面积减少(P < 0.05,P < 0.01),均优于对照组(P < 0.05);试验组血浆SOD和GSH-Px活性提高、MDA水平显著降低(P < 0.05,P < 0.01),优于对照组(P < 0.05)。
      结论  驻景丸加减方能降低干性AMD患者眼底AF强度、减少黄斑区玻璃疣面积、提高视力、降低中医证候积分,疗效机制可能与其抗氧化作用有关。

     

    Abstract:
      OBJECTIVE  To evaluate the clinical efficacy of modified Zhujing Pills in the treatment of dry age-related macular degeneration (AMD) of liver and kidney insufficiency type.
      METHODS  64 patients with dry AMD of liver and kidney insufficiency type were randomly divided into an experimental group and a control group, 32 patients each. The control group was given oral treatment with Laishiding capsules, and the experimental group was given oral treatment with modified Zhujing Pills granules. The treatment course for both groups was 3 months. Before and after treatment, the patients in the two groups were observed for TCM syndrome scores, visual acuity, fundus autofluorescence (AF), changes in drusen area within 5 mm of the fovea, and plasma superoxide dismutase (SOD), glutathione peroxidase (GSH-Px) activity and malondialdehyde (MDA) levels.
      RESULTS  After treatment, the scores of TCM syndromes in the experimental group were significantly reduced (P < 0.05, P < 0.01), and the efficacy of TCM syndromes was better than that of the control group (P < 0.01); the visual acuity of the patients in the experimental group was significantly improved, AF was significantly weakened and the area of drusen was reduced (P < 0.05, P < 0.01), which were better than those in the control group (P < 0.05); the plasma SOD and GSH-Px activities of the experimental group were increased, and the MDA level was significantly lowered (P < 0.05, P < 0.01), which were better than the control group (P < 0.05).
      CONCLUSION  Modified Zhujing Pills can reduce fundus AF intensity, decrease macular drusen area, improve visual acuity, and reduce TCM syndrome scores in patients with dry AMD. The therapeutic mechanism may be related to its antioxidant effect.

     

/

返回文章
返回